-transparent.png){kind=logo}
Osteoclasts play a critical role in bone destruction in rheumatoid arthritis. Activation of osteoclastogenesis is mediated by the enhanced expression of RANKL (receptor activator of NF-kappaB ligand), accompanied by reduced expression of its inhibitor, IFN-gamma. Accumulating evidence indicates that the osteoclast-targeted therapy is effective in arthritis models, suggesting a promising new strategy for rheumatoid bone destruction.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
Hiroshi Takayanagi
July 2013,
Nihon rinsho. Japanese journal of clinical medicine,
Hiroshi Takayanagi
September 2005,
Nihon rinsho. Japanese journal of clinical medicine,
Hiroshi Takayanagi
March 2002,
Nihon rinsho. Japanese journal of clinical medicine,
Hiroshi Takayanagi
January 1998,
Archivum immunologiae et therapiae experimentalis,
Hiroshi Takayanagi
June 2003,
Clinical calcium,
Hiroshi Takayanagi
May 2016,
Clinical calcium,
Hiroshi Takayanagi
November 1975,
The Journal of clinical investigation,
Hiroshi Takayanagi
January 2014,
Journal of immunology research,
Hiroshi Takayanagi
October 1985,
Arthritis and rheumatism,
Hiroshi Takayanagi
April 2007,
Clinical calcium,
